 La Jolla, California -- Pharmaceutical company CalciMedica has garnered $9.16 million in new venture capital debt, according to an SEC regulatory filing.
CalciMedica is focused on developing drugs for the autoimmune and inflammatory disease conditions.
Investors in the financing were not disclosed, nor was I the company intends to use the financing proceeds. |